Overview

Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF.

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to find out whether aliskiren reduces atrial fibrillation burden measured with a pacemaker device
Phase:
Phase 3
Details
Lead Sponsor:
Mika Lehto